Brinker Capital Investments LLC Purchases 17,662 Shares of CVS Health Co. (NYSE:CVS)

Brinker Capital Investments LLC increased its position in CVS Health Co. (NYSE:CVSGet Rating) by 15.8% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 129,388 shares of the pharmacy operator’s stock after acquiring an additional 17,662 shares during the quarter. Brinker Capital Investments LLC’s holdings in CVS Health were worth $13,348,000 at the end of the most recent quarter.

Other institutional investors and hedge funds have also recently made changes to their positions in the company. Segall Bryant & Hamill LLC grew its position in CVS Health by 20.9% in the 3rd quarter. Segall Bryant & Hamill LLC now owns 18,750 shares of the pharmacy operator’s stock worth $1,587,000 after purchasing an additional 3,247 shares during the last quarter. Van ECK Associates Corp grew its position in CVS Health by 1.3% in the 3rd quarter. Van ECK Associates Corp now owns 167,270 shares of the pharmacy operator’s stock worth $14,195,000 after purchasing an additional 2,191 shares during the last quarter. Financial Advocates Investment Management grew its position in CVS Health by 25.0% in the 3rd quarter. Financial Advocates Investment Management now owns 11,518 shares of the pharmacy operator’s stock worth $977,000 after purchasing an additional 2,302 shares during the last quarter. Strategic Asset Management LLC acquired a new stake in CVS Health in the 3rd quarter worth $60,000. Finally, Transcend Wealth Collective LLC grew its position in CVS Health by 3.2% in the 3rd quarter. Transcend Wealth Collective LLC now owns 16,304 shares of the pharmacy operator’s stock worth $1,440,000 after purchasing an additional 511 shares during the last quarter. Hedge funds and other institutional investors own 76.18% of the company’s stock.

Several analysts have issued reports on the stock. StockNews.com assumed coverage on shares of CVS Health in a research report on Thursday, March 31st. They issued a “strong-buy” rating on the stock. Robert W. Baird lifted their target price on shares of CVS Health from $107.00 to $110.00 in a research report on Wednesday, January 12th. Raymond James lowered shares of CVS Health from a “strong-buy” rating to an “outperform” rating and lifted their target price for the company from $115.00 to $120.00 in a research report on Friday, February 11th. Sanford C. Bernstein lifted their target price on shares of CVS Health from $111.00 to $116.00 in a research report on Tuesday, January 11th. Finally, Truist Financial lifted their target price on shares of CVS Health from $118.00 to $124.00 and gave the company a “buy” rating in a research report on Wednesday, January 5th. Four equities research analysts have rated the stock with a hold rating, eighteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Buy” and a consensus target price of $113.09.

In other news, EVP Alan Lotvin sold 21,386 shares of CVS Health stock in a transaction that occurred on Tuesday, February 1st. The shares were sold at an average price of $106.50, for a total transaction of $2,277,609.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, EVP Troyen A. Brennan sold 47,937 shares of CVS Health stock in a transaction that occurred on Thursday, February 3rd. The stock was sold at an average price of $110.00, for a total transaction of $5,273,070.00. The disclosure for this sale can be found here. In the last quarter, insiders have sold 151,606 shares of company stock valued at $15,926,821. 0.69% of the stock is owned by corporate insiders.

Shares of CVS opened at $96.13 on Friday. The business’s fifty day moving average price is $104.00 and its two-hundred day moving average price is $100.14. The firm has a market capitalization of $126.24 billion, a price-to-earnings ratio of 16.13, a PEG ratio of 1.61 and a beta of 0.80. CVS Health Co. has a 52 week low of $76.23 and a 52 week high of $111.25. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.62 and a current ratio of 0.88.

CVS Health (NYSE:CVSGet Rating) last posted its quarterly earnings results on Wednesday, February 9th. The pharmacy operator reported $1.98 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.94 by $0.04. The business had revenue of $76.60 billion for the quarter, compared to analysts’ expectations of $76.01 billion. CVS Health had a return on equity of 15.15% and a net margin of 2.71%. During the same quarter last year, the business earned $1.30 earnings per share. As a group, research analysts forecast that CVS Health Co. will post 8.23 EPS for the current year.

The firm also recently declared a quarterly dividend, which will be paid on Monday, May 2nd. Stockholders of record on Friday, April 22nd will be given a dividend of $0.55 per share. This represents a $2.20 annualized dividend and a dividend yield of 2.29%. The ex-dividend date is Thursday, April 21st. CVS Health’s dividend payout ratio is 36.91%.

CVS Health Company Profile (Get Rating)

CVS Health Corporation provides health services in the United States. The company's Health Care Benefits segment offers traditional, voluntary, and consumer-directed health insurance products and related services. It serves employer groups, individuals, college students, part-time and hourly workers, health plans, health care providers, governmental units, government-sponsored plans, labor groups, and expatriates.

Recommended Stories

Institutional Ownership by Quarter for CVS Health (NYSE:CVS)

Receive News & Ratings for CVS Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CVS Health and related companies with MarketBeat.com's FREE daily email newsletter.